Background and objective: Many studies have been conducted to investigate the association between angiotensinconverting enzyme (ACE) insertion (I)/deletion (D) gene polymorphism and vesicoureteral reflux (VUR) susceptibility. However, the results from those studies are still conflicting. We performed a meta-analysis of studies relating the ACE I/D gene polymorphism to the risk of VUR. Method: We searched the databases of PubMed, Embase, Cochrane Library and CBM-disc (China Biological Medicine Database) as of 1 March 2011, and recruited the eligible investigations for this meta-analysis. Results: Ten investigations were identified for the analysis of association between ACE I/D gene polymorphism and VUR risk: six in Caucasians, three in East-Asians and one in a Turkish population. All the investigations were performed in children. There was no marked association between ACE I/D gene polymorphism and VUR susceptibility/renal scar for overall populations, Caucasians and East-Asians. In the Turkish population, D allele and DD genotype were associated with the VUR susceptibility/renal scar. Furthermore, ACE I/D gene polymorphism was not associated with VUR progression. Conclusions: D allele and DD genotype are risk factors for the VUR susceptibility/renal scar in Turkish children. However, more case-control association investigations on larger, stratified populations are required in the future.
Introduction
Vesicoureteral reflux (VUR) is still one of the main practices of pediatric urology. 1 VUR is a common congenital disease in which urine in the bladder refluxes back into the ureters and kidneys, 2 which can cause irreversible complications such as reflux nephropathy and end-stage renal disease (ESRD). 3 VUR has been thought to be a major risk factor for renal scarring, predisposing patients to long-term kidney damage and leading to hypertension and chronic kidney insufficiency. 4 Given its major health consequences, early detection of VUR is essential to limit the sequelae of renal injury. 2 Some studies found that gene factor was associated with the risk of VUR. 2, 5, 6 The angiotensin-converting enzyme (ACE) gene consists of either an insertion (I) allele or a deletion (D) allele, forming three possible genotypes: II, ID and DD. [7] [8] [9] The ACE I/D gene polymorphism, correlating with circulating and cellular ACE concentration, [10] [11] [12] might be implicated in the etiology of VUR and has been investigated in numerous epidemiologic studies. However, the available evidence was weak, because most studies were generally small and were conducted in heterogeneous samples. There was no meta-analysis to explore the association of ACE I/D gene polymorphism with VUR risk. This meta-analysis was the first meta-analysis to investigate the relationship between ACE I/D gene polymorphism and VUR susceptibility, with the intention to provide much more reliable findings on the significance of this association.
Materials and methods

Search strategy
Search strategy for the association of ACE I/D gene polymorphism with VUR risk. The relevant studies were searched from the electronic databases of PubMed, Embase, Cochrane Library and CBM-disc (China Biological Medicine Database) on 1 March 2011. The retrieval strategy of (vesicoureteral reflux OR VUR OR reflux nephropathy) AND (angiotensin converting enzyme OR ACE) was entered into these databases mentioned above for search. The search in PubMed or Embase was limited to the English language. The search in CBM-disc was limited in abstract. Additional articles were identified through references cited in the retrieved articles.
Inclusion and exclusion criteria
Inclusion and exclusion criteria for VUR Inclusion criteria. (i) A case-control study; (ii) the outcome had to be VUR; (iii) there had to be at least two comparison groups (VUR group versus control group); (iv) investigation on the association of ACE I/D gene polymorphism with VUR risk; (v) study should be performed in children.
Exclusion criteria. (i) Review articles and editorials; (ii) case reports; (iii) investigation did not provide detailed data of ACE genotype distributions; (iv) preliminary results not about ACE I/D gene polymorphism or VUR risk; (v) investigating the relationship of ACE inhibitor to diseases; (vi) investigating the relationship of ACE level to VUR disease; (vii) studies in which the genotype distributions in the controls significantly deviated from Hardy-Weinberg equilibrium (HWE).
Data extraction and synthesis
Two investigators extracted the following information from each eligible study independently: first author's surname, year of publication and the number of cases and controls for ACE genotypes. Frequency of D allele was calculated for case group or control group, from the corresponding genotype distribution. The results were compared and disagreements were resolved by discussion.
Statistical analysis
Cochrane Review Manager Version 5 (Cochrane Library, UK) was used to calculate the available data from each investigation. The pooled statistic was counted using the fixed effects model, but a random effects model was performed when the p value of heterogeneity test was less than 0.1. Results were expressed with odds ratios (ORs) for dichotomous data, and 95% confidence intervals (CIs) were also calculated. 13 p < 0.05 was required for the pooled OR to be statistically significant. I 2 was used to test the heterogeneity among the included studies. In order to avoid excessive comparisons, the OR was calculated by using three methods: 14 method 1, allele comparison (D allele versus I allele); method 2, comparing DD homozygous with the other two combinations (DD versus DI+II); method 3, comparing II genotype with the other two combinations (II versus DD+DI). A chi-square (χ 2 ) test using a Web-based program was applied to determine whether genotype distributions of the control population reported conformed to HWE (p < 0.05 was considered significant), and the studies in which the genotype distributions in the controls significantly deviated from HWE were excluded from our meta-analysis. All descriptive data were expressed as mean ± SD.
Results
Study characteristics for VUR
A total of 205 literatures were retrieved in PubMed (47), Embase (36), Cochrane Library (2) and CBM-disc (120). There was no Chinese article meeting the inclusion criteria in this study and all the Chinese articles were excluded from our meta-analysis. Sixty-six articles published in English were excluded for reasons as follow: review articles, editorials, case reports, preliminary result not about ACE I/D gene polymorphism or outcome, investigating the relationship of ACE inhibitor to diseases, investigating the relationship of ACE level to VUR disease. Nineteen investigations were reported about the association of ACE I/D gene polymorphism with VUR susceptibility. However, four investigations 15-18 did not provide detailed data of genotype distributions of ACE I/D gene polymorphism in patients with VUR. Four studies [19] [20] [21] [22] did not include the normal control group. One study 23 was excluded from our meta-analysis for the reason that the ACE genotype distributions in the controls were significantly deviated from HWE. Finally, 10 literatures [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] were recruited into our investigation for the relationship between ACE I/D gene polymorphism and VUR susceptibility ( Figure 1 ). Interestingly, all of the investigations were performed in children. The data of our interest were extracted: first author's surname, year of publication and the number of cases and controls for ACE genotypes (Table 1 ). Those 10 investigations contained 757 case series and 1066 controls. The average frequency of ACE D allele distribution in patients with VUR for overall populations was 49.23% and the average frequency in controls was 49.24%. The average frequency of D allele distribution in Caucasians was 49.35% in cases and 53.59% for controls. Furthermore, the average frequency of D allele distribution in East-Asians with VUR was 43.02%, and the average frequency in controls was 39.15%. In the Turkish population, the average frequency of D allele distribution in VUR patients was 67.19%, and the average frequency in controls was 53.40%. The average frequency of ACE D allele in patients with VUR for overall populations was similar to that in controls (VUR/ controls = 1). The ratio of VUR/control for the average frequency of D allele distribution in the Turkish population was notably higher than that in Caucasians/ East-Asians (Turkish: VUR/control = 1.26; Caucasians: VUR/control = 0.92; East-Asians: VUR/control = 1.10).
Association of ACE I/D gene polymorphism with VUR risk
In this meta-analysis, we did not find a significant association between DD genotype or D allele and VUR risk in overall populations ( Table 2 ). The random effects OR estimated for the VUR susceptibility was 1.06 in D allele patients when compared with patients carrying I allele (95% CI: 0.83-1.36; Table 2 ), with evidence of betweenstudy heterogeneity (p = 0.002; Table 2 ). Furthermore, the fixed effects OR estimated for the risk of developing VUR was 1.21 in DD homozygous patients when compared with both other genes combined (95% CI: 0.97-1.51; Table 2 ), for the reason that the p value of heterogeneity test was less 0.15. Interestingly, we also documented that there was no significant association between II genotype and risk of VUR relative to both other genotypes combined (OR = 1.00, 95% CI: 0.61-1.62, p = 0.99; Table 2 ).
The geographic and race difference might affect the results of our analysis for the association of ACE I/D gene polymorphism with VUR susceptibility. In order to evaluate this effect, we divided the population by ethnicity. In Caucasians, there was no significant association between D allele or DD homozygous and VUR susceptibility (p = 0.55 and p = 0.27, respectively; Table 2 and Figure 2 (a) and (b)), and the II genotype seemed not to play a protective role against VUR risk (p = 0.27; Table 2 and Figure  2 (c)). In East-Asians, we found that ACE I/D gene polymorphism was not associated with VUR susceptibility (D: p = 0.31; DD: p = 0.95; II: p = 0.13; Table 2 and Figure 3 ). However, in the Turkish population, there was a significant association between ACE I/D gene polymorphism and VUR risk (D: p = 0.005; DD: p = 0.03; II: p = 0.009; Table 2 ). 
Association of the ACE I/D gene polymorphism with VUR progression
There were two investigations 26, 28 recruited into our study for the analysis of the association between ACE I/D gene polymorphism and VUR progression. All the investigations were performed in children. Lesion extent of VUR was evaluated according to the criteria in Haszon et al., 26 which divided the patients with VUR into severe group and mild group. We found that the distribution of ACE I/D gene polymorphism was not markedly different between severe group and mild group (D: OR = 0.81, 95% CI: 0.52-1.26, p = 0.35; DD: OR = 0.78, 95% CI: 0.40-1.54, p = 0.48; II: OR = 1.44, 95% CI: 0.63-3.29, p = 0.39). ACE I/D gene polymorphism might not be associated with the progression of VUR. Interestingly, those two included studies were from Caucasian populations.
Association of the ACE I/D gene polymorphism with renal scar in patients with VUR
In this study, we also investigated the difference of distribution of ACE I/D gene polymorphism between VUR patients with renal scar and VUR patients without renal scar. One study 31 did not mention the detailed sample number for VUR patients with renal scar and VUR patients without renal scar, and was excluded from our study. Finally, seven investigations were recruited into our meta-analysis: four 19, 26, 28, 29 in Caucasians, one 30 in East-Asians, and two in the Turkish population. 23, 33 All of the investigations were performed in children. We found that the difference of distribution of ACE I/D gene polymorphism between VUR patients with renal scars and VUR patients without renal scar was not statistically significant in overall populations, for Caucasians, and in East-Asians (Table 3 ). However, in the Turkish population, ACE D allele/DD genotype was associated with the risk of renal scar in patients with VUR (Table 3) .
Testing for publication bias for the analysis of association of ACE I/D gene polymorphism with VUR risk in overall populations, Caucasians and East-Asians
A funnel plot was drawn to assess the publication bias. We found that there was a significant publication bias in overall populations or in Caucasians, but there was no publication bias for East-Asian populations.
Discussion
There is increasing evidence suggesting that the renin-angiotensin system (RAS) has well-documented participation in the pathogenesis of urology diseases. Genetic markers, in particular ACE I/D gene polymorphism, might offer some benefit to better predict the outcome of urology diseases. The level of plasma ACE, constitutively expressed in several types of somatic cells, is linked to an I/D polymorphism of 287 bp in intron 16 of the ACE gene. [34] [35] [36] D allele and DD homozygote had been reported to be associated with the elevation of plasma ACE levels. [37] [38] [39] ACE is a key enzyme of RAS that can convert inactive angiotensin I into a vasoactive and aldosterone-stimulating peptide angiotensin II. [40] [41] [42] The elevation of ACE protein expression might be responsible for the elevation of plasma angiotensin II level. 43 The increased angiotensin II effects deleterious actions on the urinary tract and induces the protein expression of some other growth factors, leading to VUR. [44] [45] [46] VUR is one of the most common primary diseases leading to ESRD. Data on the risk factors for the pathogenesis of VUR were insufficient. There were only rare genetic markers to predict the risk of VUR. This meta-analysis was performed to explore whether the ACE I/D gene polymorphism could predict susceptibility to VUR. This was the first meta-analysis to explore the association of ACE I/D gene polymorphism with VUR risk. In this investigation, 10 studies were recruited: six in Caucasians, three in East-Asians and one in a Turkish population. The gene background of the Turkish population might be different from the East-Asian populations. In this study, we included four reports from Asian countries, three from Korea (East-Asians), and one from a Turkish population. We divided the studies from Asian countries included in our meta-analysis into East-Asian and Turkish populations, and analyzed them separately. We tried to review the detecting techniques for ACE genotypes in the included studies. Interestingly, the detecting techniques for ACE genotypes for VUR investigation protocols were similar in the analyzed studies. So, the pooled conclusion might be robust to some extent. The results in our study showed that the ACE I/D gene polymorphism was not a risk factor for VUR onset in Caucasians and East-Asians and for overall populations. However, there was a significant association between ACE I/D gene polymorphism and VUR susceptibility in the Turkish population. We conducted a test for publication bias in overall populations, Caucasians or East-Asian. We found that there was a significant publication bias in overall populations or in Caucasians, but there was not a publication bias in East-Asian populations. However, the number of included studies for East-Asians was small. The conclusions might be not stable for overall populations, Caucasians and East-Asians.
In Caucasians, Hohenfellner et al. 24 found that there was an association between ACE I/D gene polymorphism and the onset of VUR in American children. Haszon et al. 26 reported that ID genotype was associated with the risk of VUR in Hungarian children. However, Pardo et al. 27 and Yoneda et al. 25 conducted a study in Spanish children and Hibernian HWE: Hardy-Weinberg equilibrium; CI: confidence interval children respectively, and found that the difference of the distribution of ACE I/D genotypes between VUR group and control group was not statistically significant. Unfortunately, investigations from Sekerli et al. 28 and Savvidou et al. 29 did not show the conclusions of the association of ACE I/D gene polymorphism with VUR susceptibility.
In East-Asians, Park et al. 30 reported that the frequencies of the II, ID and DD genotypes in Korean children with 32 also reported that there were no differences in the distributions of the ACE II, ID and DD genotypes between the Korean patients with VUR and the controls. Unfortunately, the studies from Cho et al. 31 and Ozen et al. 23 did not report the conclusions of relationship between ACE I/D gene polymorphism and VUR risk. In Turkey, Erdogan et al. 33 conducted a study in children and reported that D allele was a significant risk factor for VUR patients.
Our results for the association of ACE I/D gene polymorphism with VUR risk might be more convincing when compared with those separate studies in Caucasians and East-Asians.
In this investigation, we also evaluated the association between ACE I/D gene polymorphism and VUR progression. VUR was classified as grade I-V according to the International Reflux Classification. 47 Mild-grade (grade I-III) VUR and severe-grade (grade IV and V) VUR were used to evaluate the degree of VUR progression. 26 There were two investigations 26, 28 recruited into our study for association of the ACE I/D gene polymorphism with VUR progression. We found that the distribution of ACE I/D gene polymorphism was not different between severe group and mild group. ACE I/D gene polymorphism might be not associated with the progression of VUR. Interestingly, those two included studies were from Caucasian populations, and it was difficult to draw a robust conclusion that there was an association between ACE I/D gene polymorphism and VUR progression. More investigations should be performed to explore this relation in the future.
Renal scar was an important indicator to reflect the severity of pathological change in patients with VUR. In Caucasians, Hanzon et al. 26 found that DD genotype was associated with renal scar in Hungarian children. However, Sekerli et al. 28 performed an investigation in Greek children and found that the difference of the distribution of ACE I/D genotypes between VUR patients with renal scar and VUR patients without renal scar was not statistically significant. Dudley et al. 19 conducted a study in British children and found that the distribution of ACE I/D genotypes between scar group and without scar group was not statistically different. In East-Asians, Park et al. 30 reported that ACE genotypes and allelic frequencies were not significantly different between renal scar group and without renal scar group in Korean children with VUR. However, in Turkey, Ozen et al. 23 reported that the DD genotype was associated with the onset of renal scar in Turkish children with VUR. Erdogan et al. 33 showed that the D allele was a risk factor for renal scarring in Turkish children with VUR. We found that the difference of the distribution of ACE I/D gene polymorphism between VUR patients with renal scar and VUR patients without renal scar was not markedly significant in overall populations, for Caucasians and in East-Asians. However, ACE D allele/DD genotype was associated with the risk of renal scar in patients with VUR in the Turkish population. ACE D allele/DD genotype might be a candidate factor for renal scar risk in patients with VUR in Turkish children, but not for overall populations, Caucasians and East-Asians.
VUR is associated with recurrent urinary tract infections (UTIs), 48 but not all of the VUR suffer from UTI and not all of the UTI suffer from VUR. Zaffanello et al. 49 conducted the first meta-analysis to investigate the association of ACE I/D gene polymorphism with the onset of UTI, and found that there was no marked difference between scar group and non-scar group in patients with VUR when the dominant model for ACE D allele was used. They also found that the DD genotype was a risk factor to the onset of renal scar in patients with VUR. Our meta-analysis was different from Zaffanello et al. 49 and all of the patients in our included studies were suffering from VUR (not all of the VUR suffering from UTI).
The findings mentioned above should be regarded cautiously because many other factors, such as heterogeneity of enrolled cases, limited statistical power, variable study designs and different interventions, were closely related and could affect the results. Furthermore, whether the ACE I/D gene polymorphism is just linked with other discrete loci involved in the occurrence of VUR, VUR progression or renal scar is not clear at the moment.
In conclusion, the results in our study supported that D allele/DD genotype might be a risk factor for VUR susceptibility and renal scar in Turkish children. However, this association was not found in Caucasian children, East-Asians and overall populations. Furthermore, ACE I/D gene polymorphism was not associated with VUR progression. The D allele/DD genotype might be a valuable indicator to predict the onset of VUR and renal scar in Turkish children. However, more case-control association investigations on larger, stratified populations are required to further clarify the role of ACE I/D gene polymorphism.
